112 related articles for article (PubMed ID: 30691320)
1. Myricetin nanoliposomes induced SIRT3-mediated glycolytic metabolism leading to glioblastoma cell death.
Wang G; Wang JJ; Wang YZ; Feng S; Jing G; Fu XL
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S180-S191. PubMed ID: 30691320
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
3. Role of SIRT1-mediated mitochondrial and Akt pathways in glioblastoma cell death induced by Cotinus coggygria flavonoid nanoliposomes.
Wang G; Wang JJ; To TS; Zhao HF; Wang J
Int J Nanomedicine; 2015; 10():5005-23. PubMed ID: 26345416
[TBL] [Abstract][Full Text] [Related]
4. Pluronic-based micelle encapsulation potentiates myricetin-induced cytotoxicity in human glioblastoma cells.
Tang XJ; Huang KM; Gui H; Wang JJ; Lu JT; Dai LJ; Zhang L; Wang G
Int J Nanomedicine; 2016; 11():4991-5002. PubMed ID: 27757032
[TBL] [Abstract][Full Text] [Related]
5. A Multi-targeted Natural Flavonoid Myricetin Suppresses Lamellipodia and Focal Adhesions Formation and Impedes Glioblastoma Cell Invasiveness and Abnormal Motility.
Zhao HF; Wang G; Wu CP; Zhou XM; Wang J; Chen ZP; To ST; Li WP
CNS Neurol Disord Drug Targets; 2018; 17(7):557-567. PubMed ID: 29886836
[TBL] [Abstract][Full Text] [Related]
6. The contribution of ketone bodies to glycolytic inhibition for the treatment of adult and pediatric glioblastoma.
Vallejo FA; Shah SS; de Cordoba N; Walters WM; Prince J; Khatib Z; Komotar RJ; Vanni S; Graham RM
J Neurooncol; 2020 Apr; 147(2):317-326. PubMed ID: 32096068
[TBL] [Abstract][Full Text] [Related]
7. KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice.
Polson ES; Kuchler VB; Abbosh C; Ross EM; Mathew RK; Beard HA; da Silva B; Holding AN; Ballereau S; Chuntharpursat-Bon E; Williams J; Griffiths HBS; Shao H; Patel A; Davies AJ; Droop A; Chumas P; Short SC; Lorger M; Gestwicki JE; Roberts LD; Bon RS; Allison SJ; Zhu S; Markowetz F; Wurdak H
Sci Transl Med; 2018 Aug; 10(454):. PubMed ID: 30111643
[TBL] [Abstract][Full Text] [Related]
8. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Kinetics and Mechanism of Flavonoids Extracted from Cotinus coggygria Scop. Against Glioblastoma Cancer.
Wang G; Wang JJ; Du L; Fei L; To ST
Nutr Cancer; 2016; 68(8):1357-1368. PubMed ID: 27673410
[TBL] [Abstract][Full Text] [Related]
10. High-capacity glycolytic and mitochondrial oxidative metabolisms mediate the growth ability of glioblastoma.
Kim J; Han J; Jang Y; Kim SJ; Lee MJ; Ryu MJ; Kweon GR; Heo JY
Int J Oncol; 2015 Sep; 47(3):1009-16. PubMed ID: 26202438
[TBL] [Abstract][Full Text] [Related]
11. 3-Bromopyruvate treatment induces alterations of metabolic and stress-related pathways in glioblastoma cells.
Chiasserini D; Davidescu M; Orvietani PL; Susta F; Macchioni L; Petricciuolo M; Castigli E; Roberti R; Binaglia L; Corazzi L
J Proteomics; 2017 Jan; 152():329-338. PubMed ID: 27890797
[TBL] [Abstract][Full Text] [Related]
12. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Liu YJ; Ma YC; Zhang WJ; Yang ZZ; Liang DS; Wu ZF; Qi XR
Oncotarget; 2017 Jun; 8(26):42495-42509. PubMed ID: 28477008
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG
Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886
[TBL] [Abstract][Full Text] [Related]
15. Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
Chang HH; Cheng YC; Tsai WC; Tsao MJ; Chen Y
Cell Physiol Biochem; 2018; 48(4):1694-1702. PubMed ID: 30078005
[TBL] [Abstract][Full Text] [Related]
16. Fraxinellone inhibits progression of glioblastoma via regulating the SIRT3 signaling pathway.
Shi J; Sun S; Xing S; Huang C; Huang Y; Wang Q; Xue X; Chen Z; Wang Y; Huang Z
Biomed Pharmacother; 2022 Sep; 153():113416. PubMed ID: 36076484
[TBL] [Abstract][Full Text] [Related]
17. The effect of gallic acid on cytotoxicity, Ca(2+) homeostasis and ROS production in DBTRG-05MG human glioblastoma cells and CTX TNA2 rat astrocytes.
Hsu SS; Chou CT; Liao WC; Shieh P; Kuo DH; Kuo CC; Jan CR; Liang WZ
Chem Biol Interact; 2016 May; 252():61-73. PubMed ID: 27060209
[TBL] [Abstract][Full Text] [Related]
18. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo.
Tsai NM; Lin SZ; Lee CC; Chen SP; Su HC; Chang WL; Harn HJ
Clin Cancer Res; 2005 May; 11(9):3475-84. PubMed ID: 15867250
[TBL] [Abstract][Full Text] [Related]
19. PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.
Zhao HF; Wang J; Jiang HR; Chen ZP; To SS
J Exp Clin Cancer Res; 2016 May; 35():78. PubMed ID: 27176481
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma.
Sanzey M; Abdul Rahim SA; Oudin A; Dirkse A; Kaoma T; Vallar L; Herold-Mende C; Bjerkvig R; Golebiewska A; Niclou SP
PLoS One; 2015; 10(5):e0123544. PubMed ID: 25932951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
